Hidradenitis suppurativa is a dermatological disease that affects areas of apocrine sweat glands such as buttocks, area under the breast, under the arms, inner the thighs. It is also known as acne inversa. The disease is characterized by development of follicular occlusions that lead to progressive scarring. Early symptoms of hidradenitis suppurativa include erythema and local hidradenitis, which become painful in later stages. Hidradenitis suppurativa arises as a result of hormonal imbalance, friction from clothing, and sweating. According to an article published in Current Dermatology Reports in 2014; smoking, obesity, and genetic factors are also responsible for causing the disease. The disease is more prevalent in women as compared to men, with a ratio of 3:1. Globally, the disease affects around 1% of the population. The disease is uncommon but not rare. It can occur at any age, but it is most common at the age of 20–30 years.
Based on treatment, the global hidradenitis suppurativa market has been segmented into medications, laser treatment, surgery, and others. The medications segment has been sub-segmented into biologics, antibiotics, hormonal therapy, immunosuppressive drugs, zinc supplements, retinoids, pain medication, and others. Currently, only one FDA-approved therapeutic drug i.e. adalimumab (Humira) is available for treatment of hidradenitis suppurativa. Several antibiotics, hormone therapy, and corticosteroids are prescribed off-label. Treatment of hidradenitis suppurativa still remains a challenge for scientists worldwide. Surgical removal is also a preferred mode of treatment, but the disease may relapse in other areas. Research to develop drugs for the treatment of hidradenitis suppurativa is currently in progress. As of 2017, certain drugs are under clinical development such as brilacidin, CJM 112, and xilonix. Increase in the incidence of chronic inflammatory skin diseases, the large number of ongoing clinical trials, and introduction to new treatment options are factors likely to boost the hidradenitis suppurativa market during the forecast period. However, a weak pipeline has questioned growth of the market for hidradenitis suppurativa, as most of these trials are in phase II, indicating lesser chances of approval. This factor is projected to restrain the hidradenitis suppurativa market in the near future. In addition, high cost of therapy and associated side-effects are estimated to restrain the hidradenitis suppurativa market during the forecast period.
Based on skin conditions, the hidradenitis suppurativa market has been divided into pimples, boils, deep-acne, folliculitis, and others. The folliculitis segment has been sub-segmented into hot tub folliculitis (pseudomonas folliculitis), bacterial folliculitis, pityrosporum folliculitis, barber's itch (pseudofolliculitis barbae), and others. The deep-acne segment has been further divided into blackheads, cysts, and others. The boils segment has been sub-divided into pilondial cyst, carbuncle, cystic acne, and others.
In terms of geography, the global hidradenitis suppurativa market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the global hidradenitis suppurativa market, followed by Europe. Growth of the market in North America is attributable to increase in the number of inflammatory skin conditions and the large number of ongoing clinical trials. Asia Pacific is an emerging market for hidradenitis suppurativa, due to increase in the prevalence of hidradenitis suppurativa in this region. Developing health care infrastructure and rising government expenditure on the health care industry are factors projected to boost the hidradenitis suppurativa market in Asia Pacific during the forecast period. However, factors such as low awareness among patients, high cost of therapy, and limited access to health care facilities restrain the hidradenitis suppurativa market in regions such as Middle East & Africa and Latin America.
Major players operating in the global hidradenitis suppurativa market include AbbVie Inc., AstraZeneca, Johnson & Johnson, Merck & Co., Inc., Allergan, Pfizer Inc., and GlaxoSmithKline plc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.